行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 医药生物行业周报 《药品管理法实施条例》全面修订，推 动医药产业创新与监管升级 2026 年 02 月 03 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 《聚焦脑机接口与小核酸药物，JPM 盛会 前奏下医疗布局新浪潮》 2026.01.14 《创新浪潮涌动下，医药板块修复与突破 之路》 证书编号：S1160525080001 相对指数表现 -10% 0% 10% 20% 30% 40% 2025/2 2025/8 2026/2 医药生物 沪深300 相关研究 2025.12.15 《医药生物行业 2025 年三季报财报总结： 业绩分化，医疗设备板块显现拐点》 2025.11.13 告 本周( ...

Core Viewpoint - Huate Dain (000915), focused on pediatric medication, has received a stake increase from prominent investor Guo Weisong, indicating confidence in the company's future prospects [1][3]. Group 1: Shareholding Changes - On June 17, Guo Weisong increased his stake in Huate Dain by purchasing 24,400 shares at an average price of 29.19 CNY per share, raising his total holdings to 11.7166 million shares, which constitutes 5% of the company's total share capital [1][3]. - Guo Weisong has a history of building positions in companies through private placements and has been a significant shareholder in Huate Dain since early 2024, when he held 9.2865 million shares (3.96%) [3][4]. Group 2: Financial Performance - In 2024, Huate Dain reported a revenue of approximately 2.134 billion CNY, a year-on-year decrease of 14.08%, and a net profit of about 516 million CNY, down 11.9% [5]. - In the first quarter of 2024, the company achieved a revenue of approximately 616 million CNY, reflecting a year-on-year growth of 7.78%, with a net profit of 182 million CNY, up 8.13% [6]. Group 3: Business Focus - Huate Dain's primary revenue and profit sources come from its subsidiary, Dain Pharmaceutical, which specializes in the research, production, and marketing of pediatric medications and health-related products [4]. - The main pediatric products include Yikexin, YDxin, Dain Iron, Dain Calcium, Dain Zinc, and various other medications aimed at children's health [4].